Skyrizi and Rinvoq use in gastroenterology grew over 40% year-over-year. Cantor gave AbbVie an Overweight rating with a $210 price target. Markets are messy—but the right setups can still ...

It's been a stomach-churning past few months for investors in pharmaceutical giant AbbVie (NYSE: ABBV). A potential blockbuster drug that AbbVie spent roughly $9 billion to acquire the rights to ...

In the latest market close, AbbVie (ABBV) reached $170.16, with a -1.64% movement compared to the previous day. The stock exceeded the S&P 500, which registered a loss of 2.36% for the day.

AbbVie has reported new phase 3 data for its schizophrenia and bipolar disorder therapy Vraylar in treatment-resistant depression, as it waits for a decision by the FDA on the new indication.

I'll start by comparing the revenue growth rates of AbbVie and Sanofi, then move on to discuss how often these two leaders in the autoimmune disease treatment market beat Wall Street analysts ...

AbbVie is poised to grow this year for the first time since Humira's U.S. patent expired. The dividend yields a generous 3.7% and features decades of consistent growth. While tariffs, politics ...

AbbVie stock outperformed S&P 500 with a +16% to 9.41% return since November 2023, despite Humira revenue declining 38% to $8.99 billion. Immunology drugs Skyrizi and Rinvoq grew over 50% year ...

The table above is the complete Bangalore Ramadan Calendar 2025. Here you can see the Sehri timing and iftar timing in Bangalore from the first to the last Ramadan fasting day. The Islamic and ...